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Abstract
Objective—Contemporary radiotherapy guidelines for locally advanced non-small cell lung 
carcinoma (LA-NSCLC) recommend omitting elective nodal irradiation, despite the fact that 
evidence supporting this came primarily from older reports assessing comprehensive nodal 
coverage using 3D conformal techniques. Herein, we evaluated the dosimetric implications of the 
addition of limited elective nodal irradiation (LENI) to standard involved field irradiation (IFI) 
using volumetric modulated arc therapy (VMAT) planning.
Method—Target volumes and organs-at-risk (OARs) were delineated on CT simulation images of 
20 patients with LA-NSCLC. Two VMAT plans (IFI and LENI) were generated for each patient. 
Involved sites were treated to 60 Gy in 30 fractions for both IFI and LENI plans. Adjacent 
uninvolved nodal regions, considered high risk based on the primary tumor site and extent of nodal 
involvement, were treated to 51 Gy in 30 fractions in LENI plans using a simultaneous integrated 
boost approach.
Results—All planning objectives for PTVs and OARs were achieved for both IFI and LENI 
plans. LENI resulted in significantly higher esophagus Dmean (15.3 vs. 22.5 Gy, p < 0.01), spinal 
cord Dmax (34.9 vs. 42.4 Gy, p = 0.02) and lung Dmean (13.5 vs. 15.9 Gy, p = 0.02), V20 (23.0 vs. 
27.9%, p = 0.03), and V5 (52.6 vs. 59.4%, p = 0.02). No differences were observed in heart 
parameters. On average, only 32.2% of the high-risk nodal volume received an incidental dose of 
51 Gy when untargeted in IFI plans.
Conclusion—The addition of LENI to VMAT plans for LA-NSCLC is feasible, with only 
modestly increased doses to OARs and marginal expected increase in associated toxicity.
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Introduction
Current guidelines recommend omission of elective nodal irradiation (ENI) in favor of 
involved field irradiation (IFI) in the definitive management of locally advanced non-small 
cell lung cancer (LA-NSCLC), with the rationale for this being that smaller target volumes 
enable lower rates of toxicity due to greater sparing of organs-at-risk (OARs), as well as 
improved local control by enabling dose escalation to gross disease [1, 2]. Omission of ENI 
is supported by several retrospective series showing only modest increases in nodal 
recurrence (5–10%) [3–7], as well as two randomized trials showing improvements in 
overall survival with IFI [8, 9].
However, there are several important caveats when interpreting this data. First, although 
highly conformal intensity modulated radiation therapy (IMRT) is most commonly used in 
contemporary practice, the vast majority of studies assessing ENI were carried out using 
three-dimensional conformal radiation therapy (3DCRT), which delivers a significant 
“incidental” dose to non-targeted nodal regions that may contribute towards the reportedly 
low elective nodal recurrence rate [5, 10, 11]. Delivering a similar dose to uninvolved nodal 
regions with IMRT would require explicit targeting. Furthermore, the reported rates of 
isolated regional failure may also be artificially low because of ascertainment bias, and even 
if one does assume a 5–10% regional recurrence rate, this is relatively substantial 
considering that only 15–25% of locally advanced NSCLC will be cured. Finally, the 
elective nodal volume that was historically treated (including in the above randomized trials) 
encompassed the ipsilateral hilum, entire mediastinum, and supraclavicular nodal regions, an 
immense area that would certainly cause undue cardiopulmonary toxicity. In summary, 
while data exists on all or nothing approaches to ENI using 3DCRT, there is little data on 
treating more limited elective nodal target volumes using IMRT, and it is not surprising that 
a recent survey showed great discrepancy in practice patterns for the use of various extents 
of prophylactic nodal irradiation [12].
The primary goal of this study is to determine the dosimetric impact of limited elective 
nodal irradiation (LENI) targeting prophylactic regions of the mediastinum at highest risk 
for harboring microscopic disease using modern treatment planning techniques. We 
hypothesize that the addition of these limited volumes treated to a lower dose will increase 
the dose to OARs but to a small enough degree such that all dosimetric objectives can still 
successfully be met and the expected increase in clinical toxicity is marginal.
Methods
This is a treatment planning system (TPS)-only study using CT simulation images from a 
population of 20 patients who were previously treated with definitive radiation therapy for 
locally advanced NSCLC at our institution from 2015 to 2016. Specific patients were 
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selected for inclusion such that the entire cohort would represent a variety of types of target 
volumes. For instance, we included 10 patients with hilar lymph node involvement only (N1) 
and 10 patients with mediastinal lymph node involvement (N2), and an equal number of 
patients with primary tumors located in each of the five lobes of the lung. All patients 
underwent positron emission tomography/computed tomography (PET/CT) prior to 
treatment for the purpose of staging and radiotherapy treatment planning, and lymph nodes 
were considered involved with malignancy if their short axis diameter was greater than 1 cm 
on CT or standardized uptake value (SUV) was greater than 3.0 on PET.
All treatment planning was carried out for the Varian TrueBeam linear accelerator (Varian 
Medical Systems, Palo Alto, CA) using the Eclipse treatment planning system (version 11). 
All involved field target volumes were contoured according to standard methods described in 
recent Radiation Therapy Oncology Group (RTOG) clinical trials [13]. Briefly, the gross 
tumor volume (GTV) consisted of all known gross disease based on the planning CT scan 
and pretreatment PET/CT scan. An iGTV included the union of the GTVs on all respiratory 
correlated images on a 4DCT scan acquired at the time of simulation. The clinical target 
volume (CTV) included the iGTV plus an 8-mm margin to account for miscroscopic 
extension without extending into uninvolved organs. No uninvolved (elective) nodal regions 
were added to the CTV for the IFI plans. The CTV was expanded isotropically by 5 mm to 
generate a planning target volume that was prescribed a dose of 60 Gy in 30 fractions 
(PTV60).
LENI plans utilized the same PTV60 taken to the same prescription dose as the IFI plans; 
however, an additional planning target volume encompassing adjacent nodal regions at high 
risk for harboring microscopic disease was also prescribed a dose of 51 Gy in 30 fractions 
(PTV51). The LENI plans delivered a dose to the two target volumes in a single plan via a 
simultaneous integrated boost. The high-risk nodal regions encompassed in the PTV51 were 
individualized for each patient, based on the patient’s primary tumor site and involved nodal 
stations. Table 1 shows the nodal stations considered to be at high risk in various scenarios, 
based on known patterns of nodal spread as described in previous surgical series, and 
guidelines from the LungART clinical trial for postoperative NSCLC patients in which 
elective nodal coverage is recommended [14–19]. In order to ensure accuracy of the elective 
nodal contouring, all lymph node stations were contoured as separate structures for every 
patient using the 2015 International Association for the Study of Lung Cancer (IASLC) 
lymph node map as a guideline [20]. The elective nodal CTV was generated by combining 
the contours of the nodal regions considered high risk for a given patient. A 5-mm isotropic 
expansion was added to generate the PTV51. Finally, OARs were contoured according to the 
current RTOG consensus atlas [21]. All contouring was carried out under the supervision of 
a board-certified radiation oncologist.
IFI and LENI plans were generated using volumetric modulated arc therapy (VMAT) using 
Varian Eclipse RapidArc and the Acuros 10 algorithm for dose calculations. Each plan used 
6MV photos, and either a single or double arc. Equivalent dose-volume constraints for 
PTV’s and OAR’s were used for each patient and each plan; however optimization 
conditions varied on an individual basis depending on the level of difficulty in meeting these 
constraints for each plan. Each plan was normalized such that 95% of the PTV60 received 
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100% of the prescription dose, with an acceptable maximum dose to PTV60 less than 110% 
of the prescription dose and an acceptable minimum dose to the PTV60 greater than 90% of 
the prescription dose. The OAR objectives can be found in Table 2. Figure 1 shows 
representative IFI and LENI plans.
Dose-volumetric parameters evaluated for the purpose of comparing the plans included the 
total lung V20, V5, and Dmean; heart V60, V45, V30, and Dmean; esophagus Dmax and Dmean; 
and spinal cord Dmax. Vx is defined as the volume of the OAR receiving at least dose x (Gy). 
The maximum and minimum doses were defined as the highest and lowest dose, 
respectively, within 0.03 cm3 of a given structure. IFI and LENI plans were compared using 
two-tailed Student’s t tests, for both the entire cohort and subsets of patients stratified 
according to their nodal stage (N1 vs. N2). Finally, for IFI plans, the percentage of each 
high-risk elective nodal station receiving 51 Gy was determined for each patient in order to 
determine the extent of incidental coverage. This study was approved by the local 
institutional review board.
Results
The mean (and standard deviation (STD)) dose-volumetric results for all OARs are shown in 
Table 2. Compared to IFI plans, LENI plans had higher doses to all OARs. However, the 
average LENI plans still achieved all OAR constraints. LENI resulted in significantly higher 
esophagus Dmean (15.3 vs. 22.5 Gy, p < 0.01), spinal cord Dmax (34.9 vs. 42.4 Gy, p = 0.02) 
and lung Dmean (13.5 vs. 15.9 Gy, p = 0.02), V20 (23.0 vs. 27.9%, p = 0.03), and V5 (52.6 
vs. 59.4%, p = 0.02). No statistically significant differences were observed in heart 
parameters between IFI and LENI plans. A subgroup analysis of the impact of LENI for 
stage N1 and N2 patients is shown in Supplementary Table 1. Several statistically significant 
differences were observed, though the absolute differences between IFI and LENI plans 
were comparable for N1 and N2 subgroups for each parameter.
Table 3 indicates the percentage of nodal volume outside of the PTV60 receiving at least 51 
Gy for IFI plans. On average, only 32.2% of the high-risk nodal volume targeted in LENI 
plans received an incidental dose of 51 Gy when untargeted in IFI plans. Furthermore, on 
average, only 44.9% of the uninvolved portions of involved nodal stations received an 
incidental dose of 51 Gy when untargeted in IFI plans.
Discussion
Comprehensive ENI using a 3DCRT technique has been previously shown to result in 
unfavorable outcomes compared to IFI in terms of both toxicity and tumor control. However, 
to extrapolate this data to contemporary treatment, planning techniques incorporating a more 
restricted and better selected elective nodal volume is likely to falsely exaggerate the 
disadvantages of ENI. In this treatment planning system study, we have shown that with the 
use of VMAT, the addition of LENI treated to a prophylactic dose does not impair the 
achievement of dosimetric objectives compared to standard IFI for NSCLC. Furthermore, 
contrary to prior studies assessing 3DCRT plans, we have shown that incidental dose 
deposition in these high-risk areas is minimal when not explicitly targeted using a VMAT 
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plan, and likely inadequate to sterilize microscopic disease. The implications of these 
findings are not limited to definitive treatment of LA-NSCLC, but are also relevant to small 
cell lung cancer and post-operative radiation for NSCLC, where some degree of elective 
nodal coverage is currently more accepted.
Not unexpectedly, the larger target volume in LENI plans was associated with higher dose to 
OARs despite all dosimetric objectives being achieved. An important question is how these 
observed dosimetric changes may correlate with actual risks of toxicity in patients. 
According to Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) and 
Normal Tissue Complications Probability (NTCP) models, the increase in the average mean 
lung dose from 13.5 to 15.9 Gy with LENI in this study predicts an increased risk of 
symptomatic pneumonitis of 3.1% [22]. Similarly, based on the observed increase in the 
average lung V20 from 23.0 to 27.9%, the risk of grade 2 or higher pneumonitis would be 
increased only 2–3% [23]. There is limited data available to quantify the risk of pneumonitis 
at different levels of the lung V5, though two studies suggest that an increase from 52.6 to 
59.4% should minimally increase the risk [24, 25]. The 7.2-Gy average increase in 
esophageal Dmean could increase acute esophagitis during treatment to some extent, but 
because the observed doses were all substantially lower than QUANTEC constraints, and the 
Dmax was below 60 Gy, severe esophageal toxicity would not be expected [22, 26, 27]. The 
spinal cord Dmax did not exceed 50 Gy in any plan, so no toxicity would be expected during 
or after this course of treatment [22]. Most nodes were distant from the heart, so heart 
parameters were minimally affected. For all of these reasons, we expect that the clinical 
significance of these increased doses to OARs in LENI plans is likely to be marginal.
This is not to say, though, that LENI should be used indiscriminately. For instance, in cases 
of larger, more central primary tumors with multiple involved mediastinal nodes, the 
addition of LENI may compromise esophageal constraints. Likewise, if the primary tumor 
and involved nodal areas encompass a larger longitudinal distance within the lung, 
implementing LENI may jeopardize the lungs. In our assessment, a risk-adapted approach to 
treatment planning is appropriate in which the elective target volumes are tailored to a 
patient’s individual situation, in terms of cardio-pulmonary function, age, performance 
status, and extent of disease.
The expected benefit of LENI based on this study is harder to quantify. Although regional 
recurrence is not nearly as common as distant recurrence in NSCLC, given the low cure rate 
of LA-NSCLC, LENI may better optimize the chances of cure for those patients without 
micrometastatic disease at diagnosis who have a reasonable chance at cure in the first place. 
What is clear from our data is that the concept of incidental dose going to these other 
elective nodal areas by only targeting involved areas is simply not true when advanced 
treatment planning techniques like VMAT with its much greater conformity and more rapid 
dose falloff (compared to 3DCRT) are used. Specifically, our data demonstrates that the 
percentage of nodal volume receiving 51 Gy increases from 32.2 to 99.1% with the 
incorporation of LENI. Due to the coplanar nature of most radiotherapy fields, most of this 
incidental coverage was also in the same axial plane as the gross disease, whereas minimal 
dose was deposited only a few millimeters superior to it. During surgical excision of 
NSCLC, a complete resection requires removal of at least one nodal station above the 
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highest involved station [28], yet current IFI protocols would fail to deliver dose to this same 
area unless it were explicitly targeted.
The most important limitation of this study is that it was conducted solely with a treatment 
planning software and not in actual patients. As such, we could only estimate the effects of 
the observed dosimetric changes, and assessing the clinical benefit of LENI was beyond our 
scope. While the number of patients we included would be small for a clinical trial, it is an 
adequate sample size for a treatment planning system study such as this, and a variety of 
primary tumor locations and involved nodal stations were chosen intentionally in an attempt 
to ensure that our findings were generalizable. Another potential limitation is the 
applicability of our findings to clinicians using different dose levels or other types of IMRT 
besides VMAT. The 60-Gy dose we used for involved sites is relatively standard since the 
publication of RTOG 0617 [13], and the 51-Gy dose to elective nodal stations is within the 
realm of what would be considered adequate to eradicate microscopic disease for most 
malignancies. Our integrated boost approach to delivering the dose was chosen for 
simplicity and for a fairer comparison of one IFI plan to one LENI plan (instead of two plans 
for LENI had we not used an integrated boost). Employing the same radiation technique, 
dose/fractionation, and normalization were also necessary for a fair comparison between 
planning techniques. Although the absolute differences may change slightly were we to treat 
to a higher total dose or use other forms of IMRT planning, we believe that the basic 
findings highlighted in this study would remain largely intact.
Conclusion
Herein, we have demonstrated the feasibility of the addition of LENI to standard IFI when 
using VMAT to treat patients with locally advanced NSCLC, observing only modestly 
increased doses to OARs and marginal expected increase in associated toxicity. As such, we 
believe that it should be considered for selected patients likely to benefit in clinical practice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Representative planning target volumes and isodose curves for IFI (left panel) and LENI 
(right panel) plans for a patient with an RML primary tumor and involved nodal stations 
10R, 7, 4R, and 2R
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Table 1
Thoracic nodal stations targeted for ENI based on primary tumor site and other stations involved with 
malignancy
Primary tumor site Elective nodal regions targeted
Right upper lobe All patients: 10–11R, 4R, 2R
If 2R involved, add 1R
If 4R involved, add 7
Right middle lobe All patients: 10–11R, 4R, 7
If 4R involved, add 2R
If 2R involved, add 1R
Right lower lobe All patients: 10–11R, 4R, 7
If 4R involved, add 2R
If 2R involved, add 1R
Left upper lobe All patients: 10–11L, 4L, 5, 6
If 4L or 5 involved, add 2L, 4R, and 7
If 6 involved, add 2L
If 2L involved, add 2R and 1L
Left lower lobe All patients: 10–11L, 4L, 7
If 4L involved, add 4R, 5, 6, and 2L
If 7 involved, add 4R
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